Highlights:

• This was not an “easy vaccine study”—the people who need to take part are in rural areas where clinical trials are rare.
• Engaged communities to identify and screen participants through grassroots efforts.
• Needed a dynamic site infrastructure to support participant demand and study capacity, as there is no historical knowledge of how each community would respond.